| This week's sponsor is TD2. | |  | |
Featured Story | | | Thursday, June 8, 2017 After a fairly disappointing ASCO, Roche is axing work on IDO medication indoximod and handing back the rights to partner NewLink Genetics. |
|
|
| This week's sponsor is Althea. | |  | |
Thursday, June 8, 2017 Actelion has posted mixed late-phase data on its antibiotic cadazolid. The drug, which Johnson & Johnson is set to acquire in its $30 billion (€27 billion) takeover of Actelion, failed to match an old antibiotic in one study despite holding its own in another identical trial. Thursday, June 8, 2017 Following a major reorganization earlier this year that saw it sell off its marketed med and revert back to being a clinical-stage biotech, Merrimack is making major changes in its executive team, announcing today that former Ariad chief medical officer Sergio Santillana, M.D., will be its new medical lead. Monday, June 5, 2017 As the technology landscape of clinical trials evolves, apps are engaging patients in new ways and in real time, thus becoming an integral part of the healthcare infrastructure. Thursday, June 8, 2017 Eli Lilly is paying $55 million upfront for the rights to KeyBioscience’s pipeline of treatments for Type 2 diabetes and other metabolic conditions. The agreement gives Lilly the global rights to phase 2 synthetic peptide dual amylin and calcitonin receptor agonist KBP-042 and other programs. Wednesday, June 7, 2017 Medtronic’s hybrid closed-loop system, the world’s first “artificial pancreas,” is hitting the U.S. market. The system is the only FDA-approved insulin pump that automatically delivers basal insulin to control blood glucose levels in people with Type 1 diabetes. Thursday, June 8, 2017 Formulary exclusions, pricing, biosimilars and cardiovascular outcomes data have impacted the U.S. diabetes space. We’ve compiled last year’s U.S. sales rankings for you, along with some insight into what to expect for each of the top meds going forward. Thursday, June 8, 2017 Israeli generics giant Teva Pharmaceutical Industries has chewed up three CEOs in just five years, as the company grappled with pricing pressure, declining sales growth, disappointing acquisitions and bribery investigations. Now the company says it not only wants an outsider chief, but a seasoned pharma CEO to take its helm. | | | RNAi company Dicerna Pharmaceuticals has taken on industry vet and ex-Summit Therapeutic's CMO Ralf Rosskamp, M.D., as its new chief medical officer, working on clinical development, medical affairs and regulatory functions. Release Sophiris Bio has dosed the first patient in its midstage test to assess the safety and tolerability of topsalysin in treating men with prostate cancer. Statement Cancer biopharma CytRx Corporation says it has posted an update on the regulatory pathway for an NDA submission for its aldoxorubicin in soft tissue sarcomas. Release | |
|
Resources Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. | 
